AstraZeneca said its Tezspire therapy met primary and secondary endpoints in a late-stage trial targeting eosinophilic esophagitis, a chronic inflammatory condition of the esophagus.
The study, conducted by the company, demonstrated that Tezspire significantly reduced esophageal inflammation compared with placebo. Patients treated with the drug also reported fewer episodes of swallowing difficulty and a lower frequency of swallowing issues.
Tezspire operates as a monoclonal antibody that inhibits TSLP, a protein implicated in driving inflammation linked to eosinophilic conditions and severe asthma. The drug is being developed in collaboration with Amgen.
Eosinophilic esophagitis is characterized by high levels of eosinophils in the esophagus, leading to symptoms such as pain, difficulty swallowing, and food impaction. The condition has no approved targeted therapies in the U.S. or Europe, creating an unmet medical need.
The trial results position Tezspire as a potential treatment option for patients with the condition, though further regulatory reviews and approvals would be required before commercial availability.
